Bioelectric devices and 'energy medicine': how to evaluate any device claim

What “energy medicine” covers, plainly

“Energy medicine” is a marketing umbrella that includes very different categories of intervention:

• Mainstream bioelectric devices with substantial trial evidence and TGA registration — cardiac pacemakers, implantable defibrillators, deep brain stimulators for Parkinson’s, TENS for pain, vagal nerve stimulators, spinal cord stimulators, radiofrequency ablation devices.
• Mainstream low-energy electromagnetic therapy with narrow indications — pulsed electromagnetic field (PEMF) for specific non-union fractures, transcranial magnetic stimulation for treatment-resistant depression.
• Therapy-grade devices with limited evidence in their marketed indications — broad-spectrum biofeedback devices, some classes of microcurrent therapy.
• Devices sold direct-to-consumer with broad therapeutic claims that are not on the ARTG or whose ARTG indication is narrower than the marketing suggests.

The first two categories are regulated, evidence-supported, and routine in AU clinical practice. The third has a mixed evidence base. The fourth is where most of the consumer-protection concern lives.

This page covers what the TGA actually regulates, how to check whether a specific device is included on the ARTG and for what indication, and what the questions are that a reasonable person should ask before spending substantial money on a device.

A. The AU regulatory framework — what TGA inclusion actually means

Any product making therapeutic claims in Australia must be included on the Australian Register of Therapeutic Goods before it can be lawfully imported, supplied, or advertised. Medical devices are classified into:

Class	Risk	Examples
I	Low	Bandages, examination gloves, non-invasive thermometers
IIa	Low-medium	TENS units, basic ultrasound diagnostic devices, hearing aids
IIb	Medium-high	Surgical laser, infusion pumps, anaesthesia machines
III	High	Coronary stents, breast implants, joint replacements
AIMD	Active implantable	Cardiac pacemakers, implantable defibrillators, deep brain stimulators

The TGA requires more substantial clinical evidence as the risk class rises. For Class III and AIMD, full clinical-trial evidence is generally expected before inclusion. For Class I and IIa, the evidence threshold is lower (manufacturing-quality standards, declaration of conformity, and post-market surveillance).

Inclusion is the regulatory minimum, not a quality kitemark. Two devices in the same class can both be ARTG-included while differing substantially in real-world clinical performance. For comparative effectiveness — which device works better for this patient with this condition — peer-reviewed trials and systematic reviews are the appropriate evidence source.

The ARTG indication can be narrower than the marketing claim. A device may be registered on the ARTG for, say, “stimulation of soft tissue for relief of musculoskeletal pain” — and then be marketed with broader claims about cellular healing, immune modulation, or general wellness. The legally registered indication is what the TGA assessed. The marketing claim is not.

The TGA’s Database of Adverse Event Notifications runs continuous post-market surveillance. Devices can be suspended or cancelled if safety signals emerge. The TGA advertising compliance unit and ACCC consumer-protection arm both take action against misleading therapeutic claims.

B. What the trial evidence base looks like for specific bioelectric interventions

Cardiac pacing and implantable defibrillators. Substantial trial evidence, narrow indications (specific arrhythmias, heart failure with reduced ejection fraction, certain inherited cardiac conditions). Class AIMD. ARTG-included. Mainstream cardiology.

Deep brain stimulation. Robust trial evidence for Parkinson’s disease, essential tremor, dystonia. Investigational for treatment-resistant depression. Class AIMD. ARTG-included for specific indications.

Transcranial magnetic stimulation (TMS). Approved for treatment-resistant depression, OCD, smoking cessation in specific protocols. Class IIa-IIb (depending on configuration). MBS-rebated for treatment-resistant depression since 2021. Evidence base is moderate-to-strong; effect sizes are modest but real.

Transcutaneous electrical nerve stimulation (TENS). Class IIa. ARTG-included. Used routinely in pain management, physiotherapy, and labour analgesia. Moderate evidence for specific pain indications; not a cure for chronic pain but useful in a multimodal program.

Spinal cord stimulation. Class AIMD. Used for refractory neuropathic pain, complex regional pain syndrome, failed back surgery syndrome. Evidence base growing; the trial methodology has been scrutinised and some implantation rates re-evaluated.

Vagal nerve stimulation. Class AIMD. Approved for treatment-resistant epilepsy and treatment-resistant depression. Modest effect sizes; substantial implant cost; specialist referral required.

Radiofrequency ablation. Class IIb-III. Used for cardiac arrhythmias, chronic pain (e.g. facet-joint denervation), some tumour ablation. Trial-supported in those indications.

Pulsed electromagnetic field (PEMF) therapy. Class IIa for non-union fractures (FDA-approved indication; AU usage varies). Broader claims about wellness or chronic disease are not supported by trial evidence at AU-primary-tier standards.

Microcurrent therapy and bioresonance devices. Marketed broadly. The trial evidence for these in specific therapeutic indications is mixed and generally not at AU-primary-tier standard. ARTG inclusion (where present) is often for narrower indications than the marketing suggests.

C. How to evaluate any device claim

Before paying out-of-pocket for a device — particularly one in the multi-thousand-dollar range — the AU-aligned due-diligence checklist:

1. Check ARTG inclusion. Search the ARTG database by device name or sponsor. If the device is not on the ARTG, it may not be lawfully supplied for therapeutic use in Australia. If it is, note the registered indication — this is what TGA assessed, and it may be narrower than the marketing.
2. Read the peer-reviewed evidence base. Specifically for that device, in that indication, in that patient population. A search on PubMed for “[device name] randomised controlled trial” is a reasonable start. Pay attention to sample size, blinding, comparator (placebo? sham? active comparator?), and whether the study was industry-funded or independent.
3. Look for systematic reviews and clinical guidelines. Cochrane Library, NICE, NHMRC, and Choosing Wisely Australia are all reasonable sources for whether a device has consolidated evidence for an indication.
4. Check the cost-benefit honestly. If a device costs AUD $3,000–$10,000 out-of-pocket, the same money could fund weekly accredited-allied-health sessions for two years, a comprehensive specialist workup, or significant lifestyle infrastructure changes. The opportunity cost is real.
5. Discuss with a GP. Particularly if a device is being offered for a chronic or serious condition where established treatment exists. A long consultation with a GP (MBS items 36 or 44) covers whether the underlying condition has been thoroughly worked up, whether established treatment has been adequately trialled, and whether the device under consideration fits the clinical picture.
6. Consider the marketing pattern. Broad therapeutic claims (“cellular energy”, “natural healing frequencies”, “life force”), testimonial-heavy promotion without trial data, urgency framing (“limited offer”, “before the regulators shut this down”), and direct-to-consumer sales channels are correlates of weak evidence base. The honest version exists in mainstream medical-device marketing too, but the pattern is informative.

(MBS / PBS items verified 2026-05-16 via WebSearch — workspace egress to mbsonline.gov.au + pbs.gov.au still blocked; spot-check confirms current.)

D. The honest middle ground

For someone asking should I try an energy-medicine device — the answer depends entirely on which device, for which indication, and what the trial evidence says.

Bioelectric devices in mainstream AU clinical practice (cardiac pacing, deep brain stimulation, TMS, TENS, spinal cord stimulation, vagal nerve stimulation, RF ablation) are real interventions with real indications and real evidence. They are not “alternative” — they are mainstream cardiology, neurology, pain medicine, and psychiatry. Where the indication fits, they are routine AU care, often Medicare-funded for the established indications.

Direct-to-consumer devices with broad wellness claims are a different conversation. The evidence base is generally weak by AU-primary-tier standards. The opportunity cost (cash + delayed engagement with care that might actually help) is significant. The regulatory protection (ARTG inclusion + TGA advertising oversight + ACCC consumer protection) is real but reactive — it catches misleading claims after they have been made and sold, not before.

The middle category — therapy-grade devices with specific indications, narrow evidence, sometimes used as adjuncts in multimodal care — is where most considered judgement is required. For these, the questions in section C above are the structural answer.

Sham vs placebo. A reasonable side-note: bioelectric devices are unusually well-suited to producing strong placebo effects, because they often involve a distinctive procedural experience (clinician contact, equipment use, sensation during application, structured follow-up). High-quality trials of such devices use sham devices that look identical and produce similar sensations but deliver no active treatment. Trials that do not use adequate sham controls tend to overestimate device benefit. This applies to both the mainstream and the alternative categories.

What this article is and is not

This is general health information drawn from the current Australian TGA regulatory framework, RACGP standards, Choosing Wisely Australia, the Cochrane Library, and peer-reviewed evidence on specific bioelectric devices. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about whether a specific device fits a specific clinical situation are made with your own GP and treating specialists.

This article does not name or assess any specific commercial device. The framework above applies equally to all devices in this category.

For consumer-friendly AU sources: HealthDirect, TGA consumer information, ACCC product safety.

---

Sources cited

1. TGA — Medical devices
2. TGA — Australian Register of Therapeutic Goods (ARTG)
3. TGA — Database of Adverse Event Notifications
4. TGA — Advertising therapeutic goods
5. RACGP — Standards for general practices
6. Choosing Wisely Australia
7. Australian Commission on Safety and Quality in Health Care
8. HealthDirect — Medical devices
9. Cochrane Library
10. ACCC — Health products and services
11. NICE — Medical-device guidance
12. NHMRC — Clinical reviews